Appl. no. 09/724,868 Amdt. dated September 14, 2004 Reply to Office action of 06/03/04

## **Amendments to the claims:**

This listing of claims will replace all prior versions and listings, of claims in the application:

## **Listing of Claims:**

- 1-23 (Canceled)
- 24. (Previously presented) A method of treating a B cell lymphoma in a mammal, comprising administering a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody that binds CD20, the antibody not subjected to prior lyophilization, an acetate buffer from about pH 4.8 to about 5.5, a surfactant and a polyol, wherein the formulation lacks a tonicifying amount of sodium chloride.
- 25. (Previously presented) The method of claim 24 wherein the formulation is isotonic.
- 26. (Previously presented) The method of claim 24 wherein the formulation is stable at a temperature of about 2-8°C for at least one year.
- 27. (Previously presented) The method of claim 24 wherein the formulation is stable at a temperature of about 2-8°C for at least two years.
- 28. (Previously presented) The method of claim 24 wherein the formulation is stable at about 30°C for at least one month
- 29. (Previously presented) The method of claim 24 wherein the formulation is stable following freezing and thawing of the formulation.
- 30. (Previously presented) The method of claim 24 wherein the polyol is a nonreducing sugar.
- 31. (Previously presented) The method of claim 30 wherein the nonreducing sugar is trehalose.
- 32. (Previously presented) The method of claim 30 wherein the nonreducing sugar is sucrose.
- 33. (Previously presented) The method of claim 24 wherein the antibody is an antibody fragment.

Appl. no. 09/724,868 Amdt. dated September 14, 2004 Reply to Office action of 06/03/04

- 34. (Previously presented) The method of claim 33 wherein the antibody fragment is a F(ab')<sub>2</sub>.
  - 35. (Previously presented) The method of claim 24 wherein the antibody concentration in the formulation is from about 0.1 to about 50 mg/mL.
- 36. (Previously presented) The method of claim 35 wherein the antibody is present in an amount of about 30-50 mg/mL.
- 37. (Previously presented) The method of claim 24 wherein the surfactant is a polysorbate.
- 38. (Previously presented) The method of claim 24 wherein the acetate is present in an amount of about 5-30 mM.
  - 39. (Previously presented) The method of claim 38 wherein the acetate is present in an amount of 10-30 mM.
- 40. (Previously presented) The method of claim 24 wherein the formulation further comprises a preservative.
- 41. (Previously presented) The method of claim 40 wherein the preservative is benzyl alcohol.
- 42. (Previously presented) The method of claim 24, wherein the acetate buffer is at pH 5.0.
  - 43. (Currently amended) The method of claim 24 wherein the buffer is 10-30 mM sodium acetate at pH 5, the polyol is trehalose in an amount of about 2-10% w/v, the surfactant is **a** polysorbate in an amount of about 0.01-0.1% v/v, wherein the formulation further comprises benzyl alcohol as a preservative and wherein the formulation is stable at a temperature of about 2-8°C for at least two years.
    - 44. (Canceled)